Mutations in the isocitrate dehydrogenase gene (IDH, including IDH1 and IDH2) were reported to characterize the majority of lower‐grade gliomas and to be associated with better overall survival (OS) (Parsons et al., 2008). The gene discussed is IDH2; the disease is central nervous system cancer.